Navigation Links
Nabriva Therapeutics Announces Appointment of New CEO
Date:7/2/2008

VIENNA, Austria, July 3 /PRNewswire/ -- Nabriva Therapeutics, a specialist in antibiotics development, announces that Dr. George Golumbeski has been appointed as Chief Executive Officer of the Company.

Dr. Golumbeski brings to the team nearly twenty years of industry experience serving most recently as Vice President of Business Development, Licensing & Strategy for the oncology business unit at Novartis. In this position he was responsible for the full array of business development activities leading several transactions which have resulted in projects currently in Phase III studies. While at Novartis, Dr. Golumbeski also served as a member of the Executive Committee which oversees overall oncology business performance. Prior to his tenure at Novartis, he led transactions which have resulted in two products that have been approved or are in registration in the US and the EU.

"I am excited to join Nabriva at this important stage of its growth. The Company's highly differentiated compounds have the potential to address the significant need for new classes of effective antibiotics. Furthermore, the team at Nabriva is highly experienced with a deep understanding and enthusiasm for the development of novel antibiotics," commented Dr. Golumbeski.

David Chiswell, Chair of the Supervisory Board, added, "We are pleased to welcome George to the team. His leadership skills combined with his strategic and business development insight will help position Nabriva as one of the leading specialist companies in antibiotics development."

About Nabriva Therapeutics:

Headquartered in Vienna, Nabriva Therapeutics is engaged in the discovery and development of innovative antibacterial agents addressing unmet medical need in the hospital and community setting. The company has two compounds currently in clinical trials and expects to have a third compound enter clinical trials later this year. The lead compound, BC-3205, is a parenterally and orally available pleuromutilin which is first in class and has significant market potential in multiple indications (eg. SSSI & CAP). All of Nabriva's programs are derived from compounds generated in-house through discovery activity and the company maintains an ongoing effort in medicinal chemistry.

The Company was founded in January 2006 as a spin-out of Sandoz GmbH Kundl. The spin-out was led by Nomura Phase4 Ventures with a Series A financing of EUR42 million with a syndicate that included HBM Partners, GLSV, The Wellcome Trust and Novartis Venture Fund.

Contacts:

Claudia Karner,

Tel: +43(0)1-74093-1240,

e-mail: claudia.karner@nabriva.com


'/>"/>
SOURCE Nabriva Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
2. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Duska Therapeutics Obtains Standard & Poors Listing
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
9. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
10. Barrier Therapeutics to Merge Into Stiefel Laboratories
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... DuPont ... honored with the Breakthrough Solution of the Year Award from Platts Global Energy ... ester (FDME). The award was announced at the 18th Platts Global Energy Awards, ...
(Date:12/9/2016)... TORONTO , Dec. 9, 2016 /PRNewswire/ - Portage ... Securities Exchange: PBT.U), is pleased to announce that Biohaven ... New Haven, Connecticut (PRWEB) Dec ... "Company" or "Biohaven") announced today that the U.S. Food ... drug designation request covering its drug candidate BHV-0223, an ...
(Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse┬« IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment of ... President of Eurofins Scientific Inc. (ESI). Mr. Murray ... proven professional and entrepreneurial experience in leading international business teams. As ... food testing market to uphold Eurofins, status as the global leader ... , ...
Breaking Biology Technology:
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
Breaking Biology News(10 mins):